Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study
Robert M. Grant, Marion Pellegrini, Patricia Defechereux, et al.
Clinical Infectious Diseases (2020) Vol. 73, Iss. 7, pp. e2117-e2123
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Standards of Care for the Health of Transgender and Gender Diverse People, Version 8
Eli Coleman, Asa Radix, Walter Pierre Bouman, et al.
International Journal of Transgender Health (2022) Vol. 23, Iss. sup1, pp. S1-S259
Open Access | Times Cited: 1525
Barriers and Facilitators to HIV Pre-Exposure Prophylaxis Uptake, Adherence, and Persistence Among Transgender Populations in the United States: A Systematic Review
Madeline Dang, Ayden I. Scheim, Michelle Teti, et al.
AIDS Patient Care and STDs (2022) Vol. 36, Iss. 6, pp. 236-248
Open Access | Times Cited: 60
Mapping Community-Engaged Implementation Strategies with Transgender Scientists, Stakeholders, and Trans-Led Community Organizations
Arjee Restar, Brian Minalga, Ma Irene Quilantang, et al.
Current HIV/AIDS Reports (2023) Vol. 20, Iss. 3, pp. 160-169
Open Access | Times Cited: 25
Event-driven PrEP beyond cisgender men who have sex with men
Whitney C. Irie, Melanie R. Nicol, Meredith E. Clement, et al.
The Lancet HIV (2025)
Closed Access | Times Cited: 1
Exploring barriers and facilitators to PrEP use among transgender women in two urban areas: implications for messaging and communication
Sarah Bauerle Bass, Patrick J. Kelly, Jesse Brajuha, et al.
BMC Public Health (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 31
Barriers to uptake of PrEP across the continuum among transgender women: A global scoping review
Fei Teng, Yongjie Sha, Lauren Fletcher, et al.
International Journal of STD & AIDS (2023) Vol. 34, Iss. 5, pp. 299-314
Closed Access | Times Cited: 14
Awareness and utilization of pre-exposure prophylaxis and HIV prevention services among transgender and non-binary adolescent and young adults
Arianna Rodriguez, Keith J. Horvath, Nadia Dowshen, et al.
Frontiers in Reproductive Health (2024) Vol. 5
Open Access | Times Cited: 6
Considerations for the Design of Pre-exposure Prophylaxis (PrEP) Interventions for Women: Lessons Learned from the Implementation of a Novel PrEP Intervention
Suzan M. Walters, Joey Platt, Amarachi R. Anakaraonye, et al.
AIDS and Behavior (2021) Vol. 25, Iss. 12, pp. 3987-3999
Open Access | Times Cited: 30
Perceived HIV Acquisition Risk and Low Uptake of PrEP Among a Cohort of Transgender Women With PrEP Indication in the Eastern and Southern United States
Jowanna Malone, Sari L. Reisner, Erin E. Cooney, et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes (2021) Vol. 88, Iss. 1, pp. 10-18
Open Access | Times Cited: 28
Determinants of Pre-exposure Prophylaxis (PrEP) Implementation in Transgender Populations: A Qualitative Scoping Review
Alithia Zamantakis, Dennis H. Li, Nanette Benbow, et al.
AIDS and Behavior (2022) Vol. 27, Iss. 5, pp. 1600-1618
Open Access | Times Cited: 21
Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020
Linda‐Gail Bekker, Benjamin Brown, Dvora Joseph Davey, et al.
Southern African Journal of HIV Medicine (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 29
Exploring potential drug−drug interactions between masculinizing hormone therapy and oral pre‐exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open‐label pharmacokinetic study in Thailand
Akarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen J. Kerr, et al.
Journal of the International AIDS Society (2025) Vol. 28, Iss. 4
Open Access
Drug-Drug Interactions in Transgender Patients Receiving Antiretroviral and Hormonal Therapy: A Systematic Review of Clinical Studies and Reports
R. L. Yadav, Ekta Krishna, B. K. Shrivastava, et al.
Cureus (2025)
Open Access
Global scoping review of HIV prevention research with transgender people: Transcending from trans‐subsumed to trans‐centred research
Ana María del Río‐González, María Lameiras Fernández, Djordje Modrakovic, et al.
Journal of the International AIDS Society (2021) Vol. 24, Iss. 9
Open Access | Times Cited: 22
Drug–drug interactions between gender‐affirming hormone therapy and antiretrovirals for treatment/prevention of HIV
Tessa Senneker
British Journal of Clinical Pharmacology (2024)
Open Access | Times Cited: 3
HIV Pre-Exposure Prophylaxis
Geoffroy Liégeon, Constance Delaugerre, Jean‐Michel Molina
Infectious Disease Clinics of North America (2024) Vol. 38, Iss. 3, pp. 453-474
Closed Access | Times Cited: 3
PrEP Use and Adherence Among Transgender Patients
Janelle Downing, Kimberly Yee, Jae Sevelius
AIDS and Behavior (2021) Vol. 26, Iss. 4, pp. 1251-1259
Open Access | Times Cited: 18
Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women
Asama Tanaudommongkon, Ayyappa Chaturvedula, Craig W. Hendrix, et al.
British Journal of Clinical Pharmacology (2022) Vol. 88, Iss. 8, pp. 3674-3682
Open Access | Times Cited: 13
Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate
Jenna Yager, Kristina M. Brooks, Jennifer Brothers, et al.
AIDS Research and Human Retroviruses (2022) Vol. 38, Iss. 12, pp. 939-943
Open Access | Times Cited: 12
Bidirectional pharmacokinetics of doravirine, tenofovir, and feminizing hormones in transgender women (IDentify): A randomized crossover trial
Kevin Lam, Walter K. Kraft, Tingting Zhan, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 3
Open Access | Times Cited: 2
No observed bidirectional effect between tenofovir diphosphate concentrations and gender‐affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre‐exposure prophylaxis
Nimish Patel, Sheldon Morris, Leah Burke, et al.
British Journal of Clinical Pharmacology (2024)
Open Access | Times Cited: 2
Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial
Michelle Cespedes, Moupali Das, Jenna Yager, et al.
Transgender Health (2022)
Closed Access | Times Cited: 10
Southern African HIV Clinicians Society gender-affirming healthcare guideline for South Africa
Anastacia Tomson, Christine McLachlan, Camilla Wattrus, et al.
Southern African Journal of HIV Medicine (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 13
Providing gender-affirming care to transgender and gender-diverse individuals with and at risk for HIV.
Olivia T. Van Gerwen, Jill Blumenthal
PubMed (2023) Vol. 31, Iss. 1, pp. 3-13
Closed Access | Times Cited: 5
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention
Quarraisha Abdool Karim, Derseree Archary, Françoise Barré‐Sinoussi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top